StockData

Actinium Pharmaceuticals vs Kazia Therapeutics

ATNM and KZIA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ATNM and KZIA compare

Actinium Pharmaceuticals scores higher on the StockData Score (10 against 1 for Kazia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricATNMKZIA
Size and price
Market cap$42.4M–
Share price$1.35$5.31
Change, 1 year6.3%−15.3%
Change, 5 years−81.5%−98.9%
Beta (5Y)1.384.08
Employees2514
StockData Score
Total score10 (better)1
Valuation score4 (better)0
Growth score00
Performance score1 (better)0
Health score5 (better)1
Dividend score00
Valuation
P/E3.8×–
P/B1.4×–
EV/EBITDA0.6×–
Fair value$7.16–
Margin of safety81.1%–
Growth
Revenue growth (TTM)–−98.2%
Profitability
Net margin–−49291%
Return on equity45.9%–
Financial health
Debt / equity0.00–
Current ratio4.08 (better)2.87
Altman Z-score−9.28–
Piotroski F-score22
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions16.8%0.45%
Held by insiders5.9%0.29%
Superinvestors holding–1
Short interest, % of float2.0%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.